SCHEMBL3523976

SCHEMBL3523976

Cc1nc2cc(F)ccc2n1C1C[C@H]2CC[C@@H](C1)N2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
HTT P42858 3/20 0.53
MAPK1 P28482 3/20 0.53
ALDH1A1 P00352 3/20 0.52
KDM4E B2RXH2 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
GAA P10253 1/20 0.52
PKM P14618 3/20 0.49
CYP11B1 P15538 2/20 0.47
CYP11B2 P19099 2/20 0.47
MAPT P10636 1/20 0.46
GFER P55789 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
KCNH2 Q12809 1/20 0.45
MCHR1 Q99705 1/20 0.45
GLA P06280 1/20 0.44
UBE2N P61088 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CCR5 P51681 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13543527 1.00 SMN1; SMN2 (0.53) SMN1; SMN2HTTMAPK1ALDH1A1KDM4E
SCHEMBL6017085 0.84 CCR3 (0.44) SMN1; SMN2HTTMAPK1ALDH1A1KDM4E
SCHEMBL21390931 0.82 ALDH1A1 (0.62) SMN1; SMN2HTTMAPK1ALDH1A1KDM4E
SCHEMBL988877 0.81 CCR5 (0.49) SMN1; SMN2MAPK1GAACYP11B2KCNH2
SCHEMBL4022749 0.81 CCR5 (0.49) SMN1; SMN2MAPK1GAACYP11B2KCNH2
SCHEMBL4028493 0.81 CCR5 (0.49) SMN1; SMN2MAPK1GAACYP11B2KCNH2
SCHEMBL13720260 0.81 CCR5 (0.49) SMN1; SMN2MAPK1GAACYP11B2KCNH2
SCHEMBL3863093 0.81 CCR5 (0.49) SMN1; SMN2MAPK1GAACYP11B2KCNH2
SCHEMBL3527117 0.80 LMNA (0.47) SMN1; SMN2HTTMAPK1ALDH1A1KDM4E
SCHEMBL13543524 0.80 LMNA (0.47) SMN1; SMN2HTTMAPK1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 SMN1; SMN2 4065/4885HTT 4816/4885MAPK1 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.